U.S. Cardiac Resynchronization Therapy Market

1
U.S. Cardiac Resynchronization Therapy Market

• U.S. Cardiac Resynchronization Therapy Market to
  Garner 983.3 Million by 2027 AMR

2
Covid-19 scenario

• The integration of CRT pacemaker and cardiac
  resynchronization therapy defibrillator
  significantly reduced during the Covid-19
  pandemic.
• However, the demand is expected to slowly
  increase as the market gets back to its track.
• The U.S. cardiac resynchronization therapy market
  is segmented on the basis of CRT pacemaker
  segment is estimated to manifest the highest CAGR
  of 5.7 during the forecast period. However, the
  CRT defibrillator segment held the largest share
  in 2019, accounted for more than four-fifths of
  the market.
• Read More https//www.alliedmarketresearch.com/us
  -cardiac-resynchronization-therapy-market-A10292

3
(No Transcript)
4
Leading Market Players?

• Abbott Laboratories
• Osypka Medical GmbH
• BIOTRONIK SE Co. KG
• Boston Scientific Corporation
• Medtronic plc
• LivaNova PLC
• MEDICO S.p.A.
• MicroPort Scientific Corporation
• OSCOR Inc.
• Lepu Medical Technology (Beijing) Co.

5
Analysis

• Based on end user, the specialized cardiac
  treatment centers segment is estimated to
  register the highest CAGR of 6.0 during the
  forecast period. However, the hospitals segment
  held the largest share in 2019, accounting for
  more than three-fifths of the market.

6
Contact

• David Correa5933 NE Win Sivers
  Drive205, Portland, OR 97220United StatesToll
  Free 1-800-792-5285 UK 44-845-528-1300Hong
  Kong 852-301-84916India (Pune)
  91-20-66346060Fax [phone]help_at_alliedma
  rketresearch.comWeb https//www.alliedmarketrese
  arch.com  Follow Us on LinkedIn Twitter